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Exhaled nitric oxide (FENO) has been used as a marker of asthmatic inflammation in non-occu-
pational asthma, but some asthmatics have a normal FENO. In this study we investigated
whether, normal FENO variants have less reactivity in methacholine challenge and smaller peak
expiratory flow (PEF) responses than high FENO variants in a group of occupational asthmatics.
Methods: We measured FENO and PD20 in methacholine challenge in 60 workers currently
exposed to occupational agents, who were referred consecutively to a specialist occupational
lung disease clinic and whose serial PEF records confirmed occupational asthma. Bronchial
responsiveness (PD20 in methacholine challenge) and the degree of PEF change to occupational
exposures, (measured by calculating diurnal variation and the area between curves score of
the serial PEF record in Oasys), were compared between those with normal and raised FENO.
Potential confounding factors such as smoking, atopy and inhaled corticosteroid use were
adjusted for.
Results: There was a significant correlation between FENO and bronchial hyper-responsiveness
in methacholine challenge (pZ 0.011), after controlling for confounders. Reactivity to metha-
choline was significantly lower in the normal FENO group compared to the raised FENO group
(p Z 0.035). The two FENO variants did not differ significantly according to the causal agent,
the magnitude of the response in PEF to the asthmagen at work, or diurnal variation.
Conclusions: Occupational asthma patients present as two different variants based on FENO.
The group with normal FENO have less reactivity in methacholine challenge, while the PEF
changes in relation to work are similar.
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874 V.C. Moore et al.Introduction Those with a work effect index score 2.51, (that was used
23Figure 1 The ABC plot of a worker exposed to chrome from
stainless steel welding. He has normal methacholine reactivity
(>4800 mcg) and an FENO of 6.1 ppb. The plot has a 56 L/min/h
difference between the mean curves of PEF on work and rest
days. In the bottom panel, the first row of numbers is the time
from waking in 2-hourly sections, e.g. 00e02; 02e04, etc. The
second row shows the number of readings used for the mean
PEF curves in each 2-hourly section (left side shows work
readings and right side shows rest readings). The third row
shows the area between the curves for each 2-hourly section
which are then used to calculate the ABC score which is in L/
min/h. A score of 15 L/min/h has a sensitivity of 69% and
specificity of 100% for occupational asthma diagnosis.27Measurement of exhaled breath nitric oxide (FENO) has been
promoted as a measure of airway inflammation in asth-
ma.1e4 It has been shown to be correlated with sputum
eosinophilia and non-specific reactivity in asthmatics2,4e12
but has the advantages of being less invasive for the patient
and less labour intensive for the clinician. However, some
symptomatic asthmatics have been reported to have
normal levels of FENO
7,12e14 even when factors such as
inhaled corticosteroid therapy and smoking have been
accounted for. In the diagnosis of occupational asthma, one
of the best first line investigations for occupational asthma
is serial peak expiratory flow (PEF) monitoring and is rec-
ommended by several guidelines.15,16 It has been suggested
previously that using changes in sputum eosinophil counts
between periods of exposure and non-exposure increases
the sensitivity and specificity of serial PEF measurement in
the diagnosis of occupational asthma.17 Specific inhalation
challenge tests to occupational agents have resulted in
a mean increase of exhaled nitric oxide levels.18e21
However, some workers with positive challenges have not
showed changes. We have previously found a strong positive
correlation between exhaled nitric oxide level and sputum
eosinophil count in workers with occupational asthma
exposed to low molecular weight agents and a relationship
between sputum eosinophilia and non-specific reactivity.7
The study suggested that workers can be separated into
two variants, those with eosinophilic airways inflammation
and those with non-eosinophilic inflammation and that they
would also be separable by FENO due to the strong rela-
tionship between the two indices. The aim of this study was
to see whether our retrospective analysis could be
confirmed with a prospective group, and whether the
magnitude of PEF response to occupational exposure is
related to FENO.
Methods
Study population
Consecutive workers referred to the Occupational Lung
Disease Clinic, Birmingham, UK between November 2001 and
December 2004 were recruited who had performed an
exhaled nitric oxide measurement (FENO), methacholine
challenge test and serial PEF record while still exposed at
work. Sixty subjects whose serial PEF measurements showed
occupational asthma while exposed to the causative agent
and who had a diagnosis of occupational asthma formed the
study population. The study was approved by the East Bir-
mingham Local Ethics Committee (reference 929).
Measurements
Workers were requested to record PEF every 2 h from
waking to going to bed on work days and days away from
work for a total of 4 weeks. The best of 3 PEF readings were
recorded on each occasion, provided that the best 2 read-
ings were within 20 L/min of each other. Records were
plotted, linearised22 (if recorded on a non-linear PEF
meter) and analysed by the Oasys computer program.23as a cut-off point for definite occupational effect) were
included in this analysis.
Spirometry, FENO and non-specific bronchial reactivity
in methacholine challenge were performed within 24 h of
work exposure after withholding treatment with long
acting b-agonists for 24 h (including combined steroid and
long acting b-agonists inhalers), short-acting b-agonists for
6 h and tiotropium for 36 h as part of their routine clinic
visit.
Spirometry was performed on either a wedge bellows
Vitalograph spirometer or on the Jaeger pulmonary func-
tion system according to ERS/ATS standards.24 Non-specific
bronchial reactivity to methacholine was measured using
the Yan technique.25 FENO was measured during exhalation
at 50 ml/s using the Niox from Aerocrine, which requires
values from two readings to be within 10% as recom-
mended by the ATS/ERS26 and performed before spirom-
etry. The Oasys program23 was used to calculate diurnal
variation on days at and away from work and the area
between curves (ABC) score based on mean PEF on work
days and days away from work plotted by waking time
(Fig. 1).27
Workers were split into normal and raised nitric oxide
level groups based on an eosinophil cut off of 2.2% which
was used in our previous study to separate eosinophilic and
non-eosinophilic variants.7 A cut off of 14.7 ppb for smokers
and 22.1 ppb for non-smokers (equivalent to < or 2.2%
sputum eosinophilia) was selected from a regression anal-
ysis of all our previous combined measurements of sputum
eosinophils and FENO. These values were then used to
Two variants of occupational asthma separable by exhaled breath nitric oxide level 875separate workers into those with normal FENO and those
with raised FENO levels.
Characteristics of the workers such as smoking history,
atopy (defined as at least one positive skin prick test of
3 mm wheal to a common environmental allergen using
saline and histamine as negative and positive controls) and
inhaled corticosteroid treatment were recorded. Inhaled
corticosteroids were classified into groups according to the
GINA guidelines28 for analysis against FENO.
Statistical analysis
Data was analysed by using FENO as a continuous variable
and also by grouping the workers into two variants based on
their FENO level. Physiological data were not normally
distributed, so reactivity to methacholine and nitric oxide
levels were log transformed. Subjects who had
a PD20 > 4800 mg (the highest dose used) in methacholine
challenge had their percent fall in FEV1 extrapolated to
give a PD20 value. Differences in physiological parameters
between groups were assessed using a Mann Whitney U test
or Chi-square test for non-parametric data and either
independent t-test or one-way ANOVA for parametric data
(age, FEV1 percent predicted, ABC PEF score and log
transformed reactivity to methacholine and nitric oxide).
Multiple linear regression was used for controlling for
variables potentially confounding the relation between
FENO and bronchial hyper-responsiveness. Pearson correla-
tion was used to compare reactivity to methacholine and
nitric oxide levels when using both as continuous data. The
Yates’ continuity correction was used when at least one cell
count was <5 when performing the Chi-square statistic.
SPSS version 15 was used for all statistics.
Results
Workers had a mean age of 44 years and 83% were males.
Mean FENO levels were similar between atopics and non-
atopics (p Z 0.521), males and females (p Z 0.183) and
those with an FEV1 percent predicted of <80% or >80%
(p Z 0.547). There were eighteen workers at step 4 of the
GINA treatment pathway, eleven at step 3, eight at step 2
and twenty-three on inhaled short-acting beta agonists
only. There was no difference in log FENO between theseTable 1 Characteristics of the two variants of occupational ast
Normal FENO (smokers <14.7
never/ex <22.1 ppb) n Z 25
Mean Age (SD) 43.4 (9.7)
% Male 84.0
Mean FEV1% predicted (SD) 90.7 (21.8)
% Atopic 56.0
% Using ICS 54.2
Mean ABC PEF score (SD) 38.5 (23.9)
Mean PEF work
diurnal variation (SD)
17.8 (9.4)
Mean PD20 in methacholine
challenge mg (SD)
5730 (4975)
ICS Z inhaled corticosteroidsgroups (pZ 0.591). Current smokers had significantly lower
nitric oxide levels (p Z 0.013) compared to ex or never
smokers. Those who showed bronchial hyper-responsive-
ness in methacholine challenge had a significantly higher
FENO (p Z 0.006). Table 1 shows statistical comparisons of
characteristics and physiological parameters between
raised and normal FENO groups, using the different cut-off
points for smokers and ex or never smokers.
There was a significant positive correlation between
reactivity to methacholine and nitric oxide level when both
were analysed as continuous data (Pearson
correlation Z 0.320; p Z 0.013). When controlling for
smoking, inhaled corticosteroid use and atopy (the main
determinants of nitric oxide levels) in multiple linear
regression, there was still a significant relationship
(R2Z 0.221; pZ 0.009). Fig. 2 shows the relationships split
by current smokers and ex or never smokers.
Correlations between nitric oxide level and ABC score
(as a measure of PEF response) were analysed using
multiple linear regression controlling for smoking, inhaled
corticosteroid use and atopy. There was not a significant
relationship (pZ 0.781). The ABC score was also compared
between those with raised and normal FENO levels in
a group of non-smokers who were not taking inhaled
corticosteroids. The ABC score was similar (p Z 0.912).
Diurnal variation in PEF was also similar between the two
groups (p Z 0.653).
Workers were analysed for differences in the raised and
normal nitric oxide groups according to causative agents
(Table 2). There were no differences between those with
raised and normal FENO for high versus low molecular
weight agents (p Z 0.898).
Discussion
In our study of 60 patients with occupational asthma
confirmed by their PEF record, we found that occupational
asthma patients can be divided into two variants by FENO
level and that the group with raised FENO has significantly
more reactivity in methacholine challenge. The two vari-
ants do not differ significantly according to atopy, causative
agents of occupational asthma, inhaled steroid use, or FEV1
percent predicted, indicating that these did not explain the
relation between FENO and bronchial hyper-responsiveness.hma separated by FENO level and smoking.
ppb; Raised FENO (smokers 14.7 ppb;
never/ex 22.1 ppb) n Z 35
p value
45.3 (10.1) 0.469
82.9 0.907
88.5 (18.1) 0.665
62.9 0.593
65.7 0.372
29.6 (24.9) 0.196
20.5 (12.4) 0.653
3883 (5048) 0.035
Figure 2 Scatter diagram of correlation between exhaled FENO and reactivity in methacholine challenge separated by smoking.
indicates the cut off for normal methacholine reactivity indicates the cut off separating normal
and raised FENO levels.
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PEF in response to occupational exposure, as small and
large changes in mean PEF and low and high diurnal varia-
tion were seen equally in both normal and raised FENO
groups.
Our results are compatible with others but our inter-
pretation differs. Several groups have shown that the mean
FENO increases with exposure in occupational settings, and
that there is a relationship between FENO and non-specific
bronchial reactivity in occupational and non-occupational
groups.8e12,18e21 Barbinova and Baur found that 52% of
occupational asthmatics who had non-specific bronchial
hyper-responsiveness had a >50% increase in FENO post
specific inhalation challenge test compared to 20% with
normal hyper-responsiveness.19 The mean changes have
however been driven by a subset who show changes, the
subgroup without changes in FENO have not been analysed
separately by others.Table 2 Causative occupational exposures by normal and raise
Type of occupational
exposure
Normal FENO (smokers <14.7 ppb;
never/ex <22.1 ppb) n Z 25
Metals 9
Biocides 3
Metal-working fluid 1
Isocyanates 3
Adhesives 2
Plastics 0
Other low molecular
weight agents
3
High molecular
weight agents
4
Low molecular
weight agents
21This study was designed as a follow on to the original
Anees et al. study.7 The original observation was from
a retrospective analysis, whereas the current paper is
wholly prospective data. We started with the hypothesis
generated by our previous study that there were two
variants of occupational asthma separated by FENO values
that were raised or within normal ranges while exposed,
and hypothesised that the response to occupational
exposures might differ. By analysing this prospective
group, we have confirmed that the two variants differ in
non-specific bronchial reactivity, but have not found
differences in either the agents responsible for the occu-
pational asthma nor the responses seen in the workplace
measured through serial PEFs. The results indicate that
FENO can be used without the need to measure sputum
eosinophilia, the former being a simple and cost effective
clinical measurement and the latter a much more time-
intensive process. There are centres around the world whod FENO levels.
Raised FENO (smokers 14.7 ppb;
never/ex 22.1 ppb) n Z 35
p value
11 0.711
6 0.855
5 0.383
6 0.855
2 1.000
1 1.000
0 0.133
4 0.898
31
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essential for the diagnosis of occupational asthma. In our
experience, normal non-specific reactivity is found in
w30% of workers currently exposed who have occupational
asthma. The results therefore support the inclusion of
workers with normal non-specific bronchial reactivity
within the family of occupational asthma due to sensiti-
sation. Our PEF response results agree with other studies
that have also not shown any correlation between FENO
and the magnitude of lung function (mainly FEV1) in non-
occupational asthma.9e11
We think that these two variants of occupational asthma
separable by the FENO level may be related to different
types of inflammation in the airways, the raised FENO being
related to eosinophilic inflammation and the normal FENO
perhaps to neutrophilic or other types of inflammation,
which has also been proposed by Taylor et al.29 This
hypothesis is supported by our previous finding that raised
FENO was significantly correlated with sputum eosino-
philia.7 Others have also found a linkage between eosino-
philia and raised nitric oxide levels.2,4,6 We originally
hypothesised that the occupational asthmatics with large
changes in PEF related to work exposure were more likely
to have a raised FENO than the group with small changes;
this however was not supported by our data. Whether these
two variants of occupational asthma according to FENO
level have implications for prognosis or treatment of the
disease needs to be addressed in future studies. One of the
factors relating to prognosis (FEV1% predicted) showed
similar means for those with raised and normal FENO levels
indicating that prognostic factors may only explain a small
amount of the differences in the two variants. This
outcome was significantly different in the original retro-
spective cohort, but other prognostic factors (length of
symptomatic exposure and time from first exposure to
disease onset) were similar between eosinophilic and non-
eosinophilic groups.
A number of studies have shown that inhaled cortico-
steroid use results in a fall in FENO levels in patients with
asthma.20,30e36 As the group with a raised FENO were on
more inhaled ICS than the normal group, we were unable to
find a correlation between ICS use and FENO. A small
number of patients may have been misclassified in the
normal FENO group because of this. Workers taking combi-
nation inhalers (steroid and long acting beta agonists)
would have withheld therapy for 36 h prior to the clinic
appointment for uncompromised non-specific reactivity
measurements which may have led to higher FENO levels in
this group. We also found that atopics and non-atopics had
similar FENO levels whereas other groups studying asth-
matics have found a difference.9,10,37e39 This may be due to
the fact that our cohort is a group of occupational asth-
matics which may be acting differently to general
asthmatics.Validity issues
All workers in our study had PEF records showing a work-
rest pattern compatible with occupational asthma and
Oasys score >2.51 (sensitivity of 76% and specificity of 94%
for occupational asthma23). Workers were recruitedconsecutively and were currently exposed to the sus-
pected occupational agent at the time of all investiga-
tions. There were 12 workers with normal FENO levels who
had a normal reactivity to methacholine and an FEV1
percent predicted >80%. Although some may regard these
subjects as not having occupational asthma, all of them
did fulfil the usual definitions of asthma requiring airflow
obstruction which varies over short periods of time (here
within 24 h of occupational exposures) and their mean
diurnal variation at work was 15%. All workers also had
a clear, relevant symptom history compatible with occu-
pational asthma and many were exposed to well known
causative agents. In addition, 3 had positive specific
inhalation challenge tests to the relevant occupational
allergen.
Using a cut off for FENO may have it’s limitations,
however we believe that by choosing a previously validated
cut off based on sputum eosinophilia, this problem has been
addressed. With a sample size increase, we may have seen
more difference between groups, although looking at the
data we feel this is unlikely.
Conclusions
We have identified two variants of occupational asthma
which cannot be separated according to the degree of
asthmatic reaction induced by workplace exposures or the
agents that they are exposed to, but can be separated by
measurement of exhaled nitric oxide whilst symptomatic.
The group with raised FENO levels have greater reactivity to
methacholine compared to those with normal FENO. This
could reflect different types of airway inflammation in
these two groups. Whether they differ in prognosis remains
a question to be addressed in future studies.
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